Shows
OncoTalks | Oncology Insights at Your FingertipsFrom Guidelines to Practice: Navigating Biomarker Testing in NSCLCIn this episode of OncoTalks, host Dr. Ira Zackon is joined by Dr. Alexander Spira to discuss comprehensive biomarker testing in non-small cell lung cancer (NSCLC). They unpack key findings from a recent study revealing variability in testing practices and emphasize the importance of comprehensive DNA- and RNA-based next-generation sequencing over single-gene testing. Tune in to review the latest clinical guidelines, learn how testing impacts treatment sequencing, and glean insights into how community oncology practices can overcome barriers to ensure that all NSCLC patients receive guideline-concordant testing and treatment.
Developed and produced by Ontada Learn. The content i...
2026-02-0607 minOncoTalks | Oncology Insights at Your FingertipsMicro-Series | Part 4 | Future Opportunities to Personalize Multiple Myeloma CareThis episode is part of the Micro-Series, Multiple Myeloma in 2025: Transformative Progress, the Latest Innovation, and Future Opportunities.
In the final episode of this four-part series, Dr. Mohit Narang looks ahead to emerging innovations in multiple myeloma. Learn about new therapeutic targets, MRD testing, sequencing strategies, and personalized approaches that aim to optimize outcomes and bring us closer to functional cures.
Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.
2025-12-2903 minOncoTalks | Oncology Insights at Your FingertipsMicro-Series | Part 3 | Real-World Integration of Novel Multiple Myeloma TherapiesThis episode is part of the Micro-Series, Multiple Myeloma in 2025: Transformative Progress, the Latest Innovation, and Future Opportunities.
In part three of four, Dr. Mohit Narang explores how bispecific antibodies and other advanced treatments are being implemented in real-world community oncology practices. Discover the operational challenges, safety considerations, and strategies that enable community oncology centers to expand access to these transformative therapies for the broader patient population.
Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.
2025-12-2906 minOncoTalks | Oncology Insights at Your FingertipsMicro-Series | Part 2 | Evolution of Multiple Myeloma TreatmentThis episode is part of the Micro-Series, Multiple Myeloma in 2025: Transformative Progress, the Latest Innovation, and Future Opportunities.
In part two of four, Dr. Mohit Narang examines the rapidly evolving treatment landscape for multiple myeloma. Tune in to learn how therapy has progressed from doublets to quadruplets, reshaping the role of autologous stem cell transplant, and the impact of the latest immune therapies, including monoclonal antibodies, bispecific antibody therapy, and CAR-T approaches.
Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the...
2025-12-2904 minOncoTalks | Oncology Insights at Your FingertipsMicro-Series | Part 1 | Multiple Myeloma Epidemiology, Pathophysiology and DiagnosticsThis episode is part of the Micro-Series, Multiple Myeloma in 2025: Transformative Progress, the Latest Innovation, and Future Opportunities.
In part one of four, Dr. Mohit Narang from Maryland Oncology Hematology provides a foundational overview of multiple myeloma. Tune in to learn how its incidence has evolved over the past thirty years, what we know today about disease risk factors, and the molecular mechanisms underlying multiple myeloma pathophysiology and diagnosis.
Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.
2025-12-2904 minOncoTalks | Oncology Insights at Your FingertipsCase Journey | ROS1: Transforming NSCLC Patient Outcomes through Precision Testing and Targeted TreatmentIn this OncoTalks Case Journey, Dr. Paul Conkling discusses the importance of comprehensive genomic profiling and targeted therapy in non-small cell lung cancer (NSCLC). Through the lens of two NSCLC patients who received contrasting testing and treatment, listeners learn about the actionable oncogenic biomarker ROS1, which personalized testing methods are most effective for diagnosing ROS1 variants, and the latest advancements in ROS1-targeted therapy. These cases underscore the importance of aligning therapeutic approaches with evidence-based strategies and clinical guidelines by illustrating their direct impact on patient outcomes.
Developed and produced by Ontada Learn. The content is intended f...
2025-12-1515 minOncoTalks | Oncology Insights at Your FingertipsNSCLC ROS1+ UpdatesLive from McKesson Accelerate 2025, Dr. Ira Zackon sits down with Dr. Martin Dietrich to discuss the latest in ROS1+ non-small cell lung cancer. They explore the rarity and significance of ROS1 mutations and clinical presentation. The conversation highlights evolving treatment strategies – from first-generation TKIs to next-generation options – plus safety profiles, resistance mechanisms, and NCCN guideline recommendations. Tune in for practical insights on optimizing therapy and improving outcomes for patients with ROS1+ NSCLC.
Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.
2025-11-2109 minOncoTalks | Oncology Insights at Your FingertipsThe Power of Precision Medicine for Patients with NSCLCLive from McKesson Accelerate 2025, host Suzzette Arnal talks with Dr. Melissa Johnson about how precision medicine is reshaping care for non-small cell lung cancer patients. They cover comprehensive biomarker testing, the role of DNA and RNA-based NGS, and why patient characteristics matter. Dr. Johnson also highlights breakthroughs in targeted therapies, emerging immunotherapies, and the critical role of clinical trials in improving outcomes.
Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.
2025-11-2112 minOncoTalks | Oncology Insights at Your FingertipsIMforte Trial: Redefining First-Line Maintenance Therapy in ES-SCLCIn this episode of OncoTalks, Dr. Paul Conkling and Dr. Eric Nadler take a deep dive into the IMforte trial—a pivotal phase III global study evaluating lurbinectedin and atezolizumab as a first-line maintenance therapy for extensive-stage small-cell lung cancer (ES-SCLC). They unpack the trial’s design and results, highlighting key safety and efficacy data that led to the FDA’s approval of this combination regimen on October 2, 2025. Tune in to hear expert perspectives on how this new indication will influence clinical practice and improve outcomes for ES-SCLC patients.
Developed and produced by Ontada Learn. The content is int...
2025-10-1710 minOncoTalks | Oncology Insights at Your FingertipsHow Comprehensive Molecular Profiling and AI are Shaping the Future of Cancer CareIn this episode, Dr. Paul Conkling and Dr. David Spetzler explore the advantages of broad molecular profiling over smaller panels, emphasizing its superior accuracy in detecting critical biomarkers and identifying eligibility for emerging therapies. They discuss how AI is transforming treatment sequencing and improving patient outcomes, while also highlighting key technical factors—such as microdissection and advanced extraction methods—that enhance the precision of both tissue and liquid biopsies. Dr. Spetzler further addresses the importance of high assay coverage and the role of whole exome and transcriptome sequencing in delivering comprehensive diagnostic insights, along with the challenges of clinical vali...
2025-09-1209 minOncoTalks | Oncology Insights at Your FingertipsHow MRD Testing is Reshaping Breast Cancer Recurrence MonitoringIn this episode of OncoTalks, Dr. Paul Conkling and Dr. Kashif Ali explore how minimal residual disease (MRD) testing using circulating tumor DNA (ctDNA) is reshaping breast cancer management. They discuss how this innovative approach enables the detection of molecular disease that may persist after treatment — often before clinical or radiographic signs appear. Research shows MRD testing can identify recurrence months earlier than conventional methods, allowing for timely intervention and more informed decision-making. As a result, MRD testing is becoming an increasingly valuable tool in personalized cancer care.
Developed and produced by Ontada Learn. The content is in...
2025-08-2209 minOncoTalks | Oncology Insights at Your FingertipsUnderstanding and Addressing Provider Burnout within Community OncologyIn this episode of OncoTalks, Dr. Ira Zackon, Senior Medical Director at Ontada, is joined by Dr. Marcus Neubauer, Medical Director for Professional Wellbeing at The US Oncology Network, to explore the pressing issue of provider burnout in healthcare. Together, they examine the root causes, personal and organizational impacts, and the importance of fostering a culture where provider well-being is not only supported, but expected.
Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.
2025-08-0625 minOncoTalks | Oncology Insights at Your FingertipsInnovative Genomic Profiling in HR+/HER2- Metastatic Breast CancerIn this episode of OncoTalks, Dr. Mia Levy and Dr. Paul Conkling discuss new FDA-approved treatments and therapies for HR-positive, HER2-negative metastatic breast cancer. Discover innovative genomic testing techniques that are changing the identification of mutations, paving the way for more precise treatment strategies. Tune in as we spotlight advancements in personalized breast cancer care and learn about the advantages of liquid biopsy testing.
Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.
2025-06-0610 minOncoTalks | Oncology Insights at Your FingertipsCase Journey | How ADCs are Transforming HER2-Low Metastatic Breast Cancer TreatmentTune into our debut episode of OncoTalks Case Journey as Dr. Paul Conkling and Dr. Mabel Mardones discuss two compelling cases of metastatic ER-positive breast cancer, emphasizing the role of antibody drug conjugates (ADCs) in treatment. They explore the challenges of HER2-low classification and the importance of early access to innovative therapies for improving patient outcomes. The conversation highlights the need for precise diagnostic approaches and the evolving landscape of breast cancer.
Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release d...
2025-03-3114 minOncoTalks | Oncology Insights at Your FingertipsAdvancing mCRC Care: Innovations and Insights in Modern Cancer TreatmentIn this episode of OncoTalks, Dr. Paul Conkling and Dr. David Cosgrove explore the latest advancements in mCRC treatment, highlighting the shift from traditional chemotherapy to innovative targeted therapies driven by genomic insights. We discuss the role of next-generation sequencing, new therapeutic agents, and clinical trials, while emphasizing personalized care, addressing treatment challenges, side effects, and financial considerations, offering a hopeful outlook on improved survival rates and future therapies with reduced toxicity.
Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.
2025-03-1924 minOncoTalks | Oncology Insights at Your FingertipsHER2-low Uncovered: A Phase 1 Retrospective Study on Testing & Concordant TreatmentJoin us for the conclusion of our 2-part series on HER2-low breast cancer, featuring Dr. Paul Conkling and Dr. Erika Hamilton. They discuss the Phase 1 results from a HER2-low retrospective study evaluating HER2 testing patterns and concordant therapy in patients with HER2 metastatic breast cancer. Learn about the evolving role of HER2-low classification, ongoing education, and treatment strategies to enhance patient outcomes.
Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.
2025-03-0717 minOncoTalks | Oncology Insights at Your FingertipsUnlocking the Future of Breast Cancer Treatment and the Critical Role of HER2 TestingJoin us as we explore the transformative potential of HER2 testing in breast cancer care. In this episode of OncoTalks, Dr. Paul Conkling and Dr. Erika Hamilton share cutting-edge insights that every oncologist should know to stay at the forefront of breast cancer treatment. Tune in to discover how HER2 testing is reshaping the landscape of personalized cancer therapy.
Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.
2024-12-1911 minOncoTalks | Oncology Insights at Your FingertipsGenomic Testing in the ClinicJoin Dr. Robert Reid and Dr. Sreeni Chittoor as they explore the revolutionary impact of genomic testing in redefining cancer treatment. We focus on advanced solid tumors, such as non-small cell lung cancer (NSCLC), breast cancer, and colorectal cancer, examining how these state-of-the-art technologies are leading to more personalized and effective treatment strategies.
Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.
2024-12-1115 min
Oncology Data AdvisorOntada, Microsoft, and Azure AI: Collaborating to Transform Real-Word Data Processing in OncologyIn this episode of Exploring Artificial Intelligence in Oncology, Wanmei Ou, PhD, the Vice President of Product, Clinical Decision Support, & Analytics Data Platform at Ontada, shares more about Ontada’s collaboration with Microsoft to transform unstructured oncology data with Azure OpenAI technology. Her discussion with Dr. Waqas Haque highlights how AI is transforming clinical workflows, reducing documentation burdens, and driving improved patient outcomes.
Learn more at: https://oncdata.com/ontada-microsoft-azure-ai-real-world-data-processing-in-oncology/
2024-12-1118 minOncoTalks | Oncology Insights at Your FingertipsExploring CAR-T Cell TherapyJoin Dr. Paul Conkling and Dr. Akash Mukherjee as they explore CAR-T Therapy from design of treatment through the patient journey.
Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.
2024-12-0811 minOncoTalks | Oncology Insights at Your FingertipsBispecific Antibody Therapies in the Community for DLBCL and FLJoin Dr. Ira Zackon and Dr. David Andorsky on today’s episode of OncoTalks, as they discuss the expanding role of bispecific antibody therapies in the community for Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL).
Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.
2024-11-2524 minOncoTalks | Oncology Insights at Your FingertipsDecoding METex14 Skipping in NSCLCIn this episode of OncoTalks, Dr. David Waterhouse and Dr. Paul Conkling discuss NSCLC and the groundbreaking developments in treating patients with MET exon 14 (METex14) skipping mutations. We review the science behind these targeted therapies, their clinical applications, and the impact on patient outcomes.
Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.
2024-11-1512 minOncoTalks | Oncology Insights at Your FingertipsExploring Second Line Treatments for Extensive Stage Small Cell Lung CancerIn this episode, Dr. David Waterhouse and Dr. Paul Conkling discuss the evolving landscape of second line treatments for extensive stage small cell lung cancer (SCLC). They review the latest research, promising therapies, and the impact of these treatments on patient quality of life. This episode offers vital information to help navigate treatment options and empower patients. Don’t miss this engaging discussion on a crucial topic in oncology, filled with expert insights!
Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release da...
2024-10-3014 min
The Collective Voice of Health IT, A WEDI PodcastEpisode 142: Health Equity Sit Down with Dr. Vindell Washington of Verily Health PlatformsAt WEDI's recent Health Equity Forum and Workshop, Sagran Moodley, Chief Innovation and Technology Officer with Ontada spoke with Dr. Vindell Washington, former National Coordinator for Health IT and the Chief Clinical Officer and Director of the Health Equity Center of Excellence for Verily Health Platforms.
2024-02-2328 min
PeerView Clinical Pharmacology CME/CNE/CPE VideoJoyce O’Shaughnessy, MD - Custom Care Compass: Mastering Multifactorial Clinical Decision-Making in High-Risk HR+, HER2- MBCThis content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/RRR865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until February 9, 2025.Custom Care Compass: Mastering Multifactorial Clinical Decision-Making in High-Risk HR+, HER2- MBC In support of improving patient care, PVI, PeerView Institute for...
2024-02-1356 min
PeerView Oncology & Hematology CME/CNE/CPE Audio PodcastJoyce O’Shaughnessy, MD - Custom Care Compass: Mastering Multifactorial Clinical Decision-Making in High-Risk HR+, HER2- MBCThis content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/RRR865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until February 9, 2025.Custom Care Compass: Mastering Multifactorial Clinical Decision-Making in High-Risk HR+, HER2- MBC In support of improving patient care, PVI, PeerView Institute for...
2024-02-1356 min
PeerView Oncology & Hematology CME/CNE/CPE Video PodcastJoyce O’Shaughnessy, MD - Custom Care Compass: Mastering Multifactorial Clinical Decision-Making in High-Risk HR+, HER2- MBCThis content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/RRR865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until February 9, 2025.Custom Care Compass: Mastering Multifactorial Clinical Decision-Making in High-Risk HR+, HER2- MBC In support of improving patient care, PVI, PeerView Institute for...
2024-02-1356 min
PeerView Clinical Pharmacology CME/CNE/CPE Audio PodcastJoyce O’Shaughnessy, MD - Custom Care Compass: Mastering Multifactorial Clinical Decision-Making in High-Risk HR+, HER2- MBCThis content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/RRR865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until February 9, 2025.Custom Care Compass: Mastering Multifactorial Clinical Decision-Making in High-Risk HR+, HER2- MBC In support of improving patient care, PVI, PeerView Institute for...
2024-02-1356 min
Empowered Patient PodcastValue of Real-World Data in Oncology Drug Development and Clinical Trials with Vasu Chandrasekaran Ontada TRANSCRIPT Vasu Chandrasekaran, VP of real-world data and analytics at Ontada, provides an electronic health record platform, iKnowMed, used by community oncology providers to practice evidence-based and patient-centered medicine better. They also work closely with the US Oncology Network to improve access to new therapies and clinical trials. Using real-world data to generate real-world evidence allows Ontada to drive drug discovery and development, conduct more diverse trials, and better understand the effectiveness of treatments. Vasu explains, "Community oncology is where most of the cancer care happens. We enable those physicians in the community to practice evidence-based and patient-centered m...
2023-12-0500 minEmpowered Patient PodcastValue of Real-World Data in Oncology Drug Development and Clinical Trials with Vasu Chandrasekaran Ontada Vasu Chandrasekaran, VP of real-world data and analytics at Ontada, provides an electronic health record platform, iKnowMed, used by community oncology providers to practice evidence-based and patient-centered medicine better. They also work closely with the US Oncology Network to improve access to new therapies and clinical trials. Using real-world data to generate real-world evidence allows Ontada to drive drug discovery and development, conduct more diverse trials, and better understand the effectiveness of treatments. Vasu explains, "Community oncology is where most of the cancer care happens. We enable those physicians in the community to practice evidence-based and patient-centered m...
2023-12-0519 min
Profiles in LeadershipAndy Moye, CEO: AI a Tool for Medicine to help Make Diagnosis More AccurateAndy Moye is a seasoned commercial leader and corporate development executive who has worked across the molecular diagnostics, biotechnology and life sciences industries. He is currently Chief Executive Officer at Paige and previously served as Chief Commercial Officer, where he led the company’s clinical sales and commercial strategy, including the U.S. launch of Paige Prostate, the first and only AI-based pathology product to receive FDA approval for in vitro diagnostic (IVD) use in detecting cancer in prostate biopsies. Previously, Moye served as Head of Commercial Operations in North America and Latin America for the...
2023-11-0858 min
Health Professional Radio - PodcastNew Research Shows How Social Determinants of Health Impact Different Patient Populations with Triple-Negative Breast CancerDr. Nicholas Robert, CMO of Ontada, discusses new research that examines potential factors that may impact care and outcomes for affected communities with a common and aggressive form of cancer, Triple Negative Breast Cancer.
#rwd #sdoh #rwe
In his role as Chief Medical Officer, Dr. Robert is responsible for deepening Ontada’s clinical focus and expertise. As the senior clinical leader at Ontada, Dr. Robert collaborates across the organization to ensure studies, real-world data offerings and educational programs maintain the highest scientific standards and clinical relevance. He also collaborates with physicians and physician-led groups, including The US...
2023-08-0210 min
Tech Gals19. Data Science in Healthcare & Experiences as a Woman Working Abroad ft. Nadaa TaiyabNadaa Taiyab is a senior data scientist at Ontada (McKesson, which is a healthcare company for wholesale medical supplies, equipment, pharmaceutical distribution, and healthcare technology solutions.) However, she was actually pre-med and majored in international relations. Her data science career began 15+ years after her first full time job out of college after taking an intensive 3-month bootcamp (from Galvanize). We talk about the applications of data science in healthcare and cool projects that Nadaa has worked on. Her experiences traveling and working abroad as a young female and what she's learned from transition careers and becoming a mother.
2021-04-1240 min